Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464110 | 0.85 | CA2 (0.51) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL27674218 | 0.85 | SMN1; SMN2 (0.53) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL18506590 | 0.83 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12175416 | 0.79 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5989989 | 0.78 | CA2 (0.41) | CA2 | |
| SCHEMBL5989992 | 0.78 | CA2 (0.41) | CA2 | |
| SCHEMBL30040716 | 0.75 | CA2 (0.35) | CA2 | |
| SCHEMBL29204050 | 0.75 | CA2 (0.35) | CA2 | |
| SCHEMBL29204089 | 0.75 | CA2 (0.35) | CA2 | |
| SCHEMBL27292255 | 0.75 | CA2 (0.48) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | BERRY & ASSOCIATES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1831238-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Berry & Associates , Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060178507-A1 | Fluorous oligonucleotide reagents and affinity purification of oligonucleotides | BERRY & ASSOCIATES, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006081035-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | BERRY & ASSOCIATES, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178507-A1 | Fluorous oligonucleotide reagents and affinity purification of oligonucleotides | DCLRE1B, POLM, FBL | CA2 3558/4885TSHR 628/4885SMN1; SMN2 3305/4885 |
| US-20100087634-A1 | Fluorous Oligonucleotide Reagents and Affinity Purification of Oligonucleotides | DCLRE1B, POLM, FBL | CA2 3558/4885TSHR 628/4885SMN1; SMN2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.